GoodRx (NASDAQ:GDRX) Stock Falls 8.8% – Should You Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) shares traded down 8.8% on Thursday. The stock traded as low as $3.11 and last traded at $3.0640. 861,284 shares changed hands during trading, a decline of 52% from the average daily volume of 1,808,294 shares. The stock had previously closed at $3.36.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. UBS Group raised their target price on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of GoodRx in a report on Wednesday, November 4th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. TD Cowen raised their price target on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price target on GoodRx in a report on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.15.

Read Our Latest Analysis on GoodRx

GoodRx Stock Down 9.7%

The stock has a market capitalization of $1.04 billion, a P/E ratio of 75.89 and a beta of 1.66. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock’s fifty day moving average is $3.44 and its two-hundred day moving average is $2.89.

Insider Transactions at GoodRx

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 1,841,761 shares of company stock valued at $6,432,783. 5.87% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

Hedge funds have recently added to or reduced their stakes in the company. Focus Advisor Solutions LLC purchased a new stake in shares of GoodRx in the third quarter worth approximately $33,000. Headlands Technologies LLC bought a new stake in GoodRx in the 2nd quarter worth about $30,000. R Squared Ltd bought a new stake in GoodRx during the third quarter worth $36,000. Essential Partners LLC boosted its position in GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock worth $28,000 after purchasing an additional 11,295 shares during the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of GoodRx by 36.4% in the 3rd quarter. Royce & Associates LP now owns 51,974 shares of the company’s stock worth $171,000 after buying an additional 13,860 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions. The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients.

Featured Articles

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.